Obama Sends Biotech Industry an Early Christmas Gift
The Bedford Report Provides Analyst Research on Geron & AEterna Zentaris
NEW YORK, NY, Dec 10, 2010 (MARKETWIRE via COMTEX) -- Biotech companies haven't
been impervious to the economic downturn but they have endured better than most.
This is partly due to the fact that demand for pharmaceuticals remains fairly
constant even during recession. At the moment there is plenty of optimism
regarding the Biotech Industry as firmer pricing and new products have improved
sales and earnings trends this year. While healthcare reform is likely to shake
up this industry, gestures of goodwill from the Obama administration have
curtailed some concern. The Bedford Report examines the outlook for companies in
the Biotechnology Industry and provides research reports on Geron Corporation
(GERN) and AEterna Zentaris, Inc. (AEZS). Access to the full company reports can
be found at:
bedfordreport.com
bedfordreport.com
Recently the Obama administration pressed congress to revamp a research and
development tax credit by increasing it by about 20 percent and make it
permanent. The Pharmaceutical Research and Manufacturers of America, PhRMA, as
well as the Advanced Medical Technology Association expressed support for the tax
credit.
The Bedford Report releases regular market updates on the Biotechnology Industry
so investors can stay ahead of the crowd and make the best investment decisions
to maximize their returns. Take a few minutes to register with us for free at
bedfordreport.com and get exclusive access to our numerous analyst
reports and industry newsletters.
A recent survey from PricewaterhouseCoopers found that life sciences firms
believe that industry-FDA relationships have improved since Obama took office. In
fact, 80% of the survey said in the last two years the FDA has provided better
guidance about its expectations.
In recent FDA-Biotech industry news, last month the FDA famously approved a human
trial of a therapy developed from embryonic stem cells which will be used to
treat individuals suffering from an eye condition that can lead to blindness.
The Bedford Report provides Analyst Research focused on equities that offer
growth opportunities, value, and strong potential return. We strive to provide
the most up-to-date market activities. We constantly create research reports and
newsletters for our members. The Bedford Report has not been compensated by any
of the above mentioned companies. We act as an independent research portal and
are aware that all investment entails inherent risks. Please view the full
disclaimer at: bedfordreport.com. |
